Characterisation of silica-based heparin-affinity adsorbents through column chromatography of plasma fractions containing thrombin.
Different heparin-silicas, synthesised in this laboratory via directional end-point attachment of heparin (H) onto various amino-derivatised silicas, have been evaluated in packed-bed and expanded-bed column chromatographic experiments using crude preparations of the therapeutic protein, thrombin (T). Adsorbent capacities, determined through batch adsorption experiments, were verified by employing frontal analysis in packed-bed systems. The performance of these adsorbents was also investigated in terms of thrombin purification factors and recoveries. The potential of the heparin-silicas was further examined in the expanded-bed column chromatographic mode using a scaled-up procedure. With heparin-Fractosil 1000 adsorbents, capacities of around 100,000 U thrombin/ml adsorbent could be achieved. Heparin-Fractosil 1000 adsorbents of intermediate heparin content (around 4 mg heparin/ml sorbent) displayed binding stoichiometries similar to that of the commercial heparin-Sepharose (2.6-2.7 mol T/mol H). Furthermore, binding stoichiometries were largely unaffected by increasing the heparin content on the heparin-Fractosil 1000 adsorbents from 0.8 to 4.6 mg of heparin/ml of sorbent. This result suggests that optimal binding site accessibilities for the thrombin-heparin interaction occurs at lower ligand density values. The binding capacity values determined from frontal analysis were confirmed by the recovery data, thus indicating minimal irreversible adsorption. Specific activities of ca. 2100 U/mg were obtained for thrombin when affinity-purified on these heparin-LiChroprep Si60 or heparin-Fractosil 1000 adsorbents. These values were higher than the maximum achievable purity obtained through alternative, multi-step chromatographic purification procedures reported by other investigators. These results indicated that the packed-bed performances with these silica-based adsorbents were superior to currently available commercial soft gel adsorbents, with the more dense heparin-silicas exhibiting very good potential for use in expanded-bed applications.
Björklund
M
M
Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia.
Hearn
M T
MT
D000327:Adsorption; D001665:Binding Sites; D002847:Chromatography, Agarose; D002853:Chromatography, Liquid / Q000379:methods*; D004591:Electrophoresis, Polyacrylamide Gel; D006493:Heparin / Q000032:analysis / Q000737:chemistry*; D006801:Humans; D009994:Osmolar Concentration; D011933:Reagent Kits, Diagnostic; D012822:Silicon Dioxide / Q000737:chemistry*; D013917:Thrombin / Q000032:analysis / Q000737:chemistry* / Q000302:isolation & purification*
D011933:Reagent Kits, Diagnostic; D012822:Silicon Dioxide; D006493:Heparin; D013917:Thrombin